Research & Development
-
How a SpaceX mission could speed drug discoveries on Earth
Research enabled by blasting off into space could lead to better treatments for diseases such as ALS and Parkinson’s.
By Kelly Bilodeau • Aug. 28, 2025 -
A brewing GLP-1 showdown, from Big Pharma pills to a biotech implant
Newcomers looking for a way into the obesity space are developing unique methods to snag market share.
By Amy Baxter • Aug. 27, 2025 -
Explore the Trendline➔
Stock via Getty ImagesTrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
AbbVie dives back into the neuro pool with a $1.2B psychedelics play
Following a major clinical failure last year, AbbVie’s purchase of a psychedelic depression treatment has the potential to revive a touch-and-go market.
By Michael Gibney • Aug. 26, 2025 -
And just like that... pharma’s breakups reveal pain points in cancer R&D
Biotech tie-ups with Gilead, Genetech and Ipsen that have recently been let go.
By Meagan Parrish • Aug. 22, 2025 -
Q&A
In cell therapy, cost is a hot issue. The industry might need a cold solution.
The logistical linchpin of cryopreservation could make a challenging space more accessible.
By Michael Gibney • Aug. 19, 2025 -
Merck KGaA ventures into new territory in the US
How the president of EMD Serono, Merck KGaA, Darmstadt, Germany’s U.S. arm, is leading the charge to “double down” on new innovation.
By Alexandra Pecci • Aug. 15, 2025 -
With scrapped mRNA funding, a vaccine maker finds a silver lining
While mRNA is suffering the brunt of the MAHA movement with $500 million in funding cuts, other vaccine makers could fill some of that void.
By Michael Gibney • Aug. 14, 2025 -
3 ways the GLP-1 market has changed shape this year
Novo Nordisk and Eli Lilly’s quarterly earnings revealed shifting dynamics in the lucrative obesity space.
By Amy Baxter • Aug. 12, 2025 -
Are stem cell therapies ready for pharma’s prime time?
Stem cell therapies are thriving on the fringes of healthcare — but science-backed treatments are also poised to make an impact in pharma R&D.
By Kelly Bilodeau • Aug. 11, 2025 -
As gene therapies falter on the market, this biopharma is aiming to defy the odds
After a strong launch for its cancer gene therapy, Ferring Pharmaceuticals is setting the stage for long-term growth.
By Meagan Parrish • Aug. 8, 2025 -
Q&A
Inside AstraZeneca’s long-game strategy in lung cancer
New long-term results for Tagrisso in EGFR-mutated non-small cell lung cancer showcase a precision approach the company has honed for decades.
By Michael Gibney • Aug. 7, 2025 -
David Altshuler, geneticist who helped transform Vertex, to retire next year
Since becoming Vertex's top scientist in 2015, Altshuler has helped the company become an industry powerhouse. He’ll depart next year in a “planned transition.”
By Ben Fidler • Aug. 5, 2025 -
Merck & Co. assembles an Alzheimer’s comeback with a next-gen precision focus
With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater understanding of its drivers.
By Michael Gibney • Aug. 1, 2025 -
Roche pushes ahead with late-comer strategy in obesity
The Swiss pharma company announced several updates to its obesity portfolio in its latest earnings report.
By Amy Baxter • July 30, 2025 -
Biotech investing is down, but some VC firms are bucking the trend
Discipline is the name of the game after a glut of over-investing burst the biotech bubble.
By Alexandra Pecci • July 29, 2025 -
Could bispecifics unseat Keytruda from its oncology throne?
Signals suggest the drugs could improve on the standard of care, but the market may not make it easy for another megablockbuster to rise to the top.
By Kelly Bilodeau • July 28, 2025 -
From the bench: Researchers make NIH-funded preclinical strides in mRNA and obesity
The studies are contributing preclinical advances for some of the world’s biggest blockbusters.
By Michael Gibney • July 25, 2025 -
How Bristol Myers Squibb uses AI to validate drugs before they’re even in the lab
The company’s AI approach allows molecule candidates to be vetted for efficacy and other properties early in development.
By Alexandra Pecci • July 24, 2025 -
Who is Dr. George Tidmarsh, the new director of CDER?
Despite past criticism of public health policies, Tidmarsh recently praised the FDA and said he’ll focus on boosting review efficiencies.
By Meagan Parrish and Michael Gibney • July 23, 2025 -
Sponsored by TriNetX
Closing the gap: How real-world data and artificial intelligence are reinventing the last mile of clinical research
Clinical trial delays are costly—here’s how RWD and AI are transforming recruitment and retention.
July 21, 2025 -
FDA invites more data from abroad — with a wary eye on China
The FDA approved four drugs last year without any U.S. trial participants, but has maintained a tougher stance on China, even as it grows into an R&D powerhouse.
By Amy Baxter • July 16, 2025 -
With Verona deal, Merck wagers on strength of lung drug’s patents
The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make good on the deal, other secondary patents will need to hold up.
By Jonathan Gardner • July 11, 2025 -
Early measles drug R&D kicks into gear as U.S. records record outbreak
Several companies have announced preclinical efforts to develop the first-ever measles treatment.
By Meagan Parrish • July 11, 2025 -
First 90 Days
As its cancer vaccine moves through the clinic, Transgene sets sights on manufacturing
Simone Steiner recently joined the French company to set the stage for launch.
By Amy Baxter • July 9, 2025 -
The MEK effect on cancer — a slow and steady approach to drug resistance
Immuneering Corporation’s investigational MEK inhibitor aims to outpace cancer while reducing resistance and side effects.
By Kelly Bilodeau • July 8, 2025